4576.T
D.Western Therapeutics Institute, Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 61.00
−1.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 306.0M | 387.0M | 471.0M | 428.0M | 448.0M |
| Cost of Revenue | — | 38.9M | 46.8M | 36.7M | 27.6M |
| Gross Profit | 15.1M | 348.8M | 424.7M | 391.7M | 420.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 182.4M | 968.6M | 1.6B | 1.2B | 726.4M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 182.4M | 968.6M | 1.6B | 1.2B | 726.4M |
| Cost and Expenses | 950.0M | 1.0B | 1.7B | 1.2B | 753.0M |
| Operating Income (EBIT) | (644.0M) | (619.0M) | (1.2B) | (798.0M) | (305.0M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 2.1M | 76.0K | 10.0K | 25.0K |
| Interest Expense | 3.2M | 8.8M | 5.2M | 2.5M | 3.1M |
| Net Interest Income | (1.9M) | (6.8M) | (5.1M) | (2.5M) | (3.1M) |
| Other Non-Op Income/Expense | (3.1M) | (10.6M) | (18.5M) | 2.2M | 10.1M |
| Non-Operating Income (excl Interest) | 14.0K | 8.2M | 2.0M | 6.7M | 38.5M |
| EBT (Pre-Tax Income) | (170.4M) | (630.5M) | (1.3B) | (826.8M) | (440.3M) |
| Income Tax Expense | 398.0K | 1.6M | 1.6M | 1.6M | 1.6M |
| Bottom Line | |||||
| Net Income | (652.0M) | (632.0M) | (1.3B) | (812.0M) | (429.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (652.0M) | (632.0M) | (1.3B) | (812.0M) | (429.0M) |
| Per Share | |||||
| Basic EPS | (¥14) | (¥13) | (¥37) | (¥26) | (¥15) |
| Diluted EPS | (¥14) | — | — | — | — |
| Revenue Per Share | ¥6 | ¥8 | ¥13 | ¥13 | ¥15 |
| Shares | |||||
| Basic Shares Outstanding | 54.4M | 47.9M | 35.1M | 31.8M | 29.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (571.5M) | (1.2B) | (749.3M) | (258.6M) |
| D&A | — | 47.5M | 49.3M | 48.7M | 46.4M |
| EBIT | (644.0M) | (619.0M) | (1.2B) | (798.0M) | (305.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026